New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Sarepta Therapeutics, Inc.
SRPT
Shape
US Flag

NASDAQ

12B

Biotechnology

Next Earning date - 06 Nov 2024

12B

Biotechnology

Next Earning date - 06 Nov 2024

127.08USD
Shape2.83 ( 2.28%)
favorite-chart

Relative Strenght

23
favorite-chart

Volume Buzz

-4%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

27%

Quote Panel

Shape
Updated October 20, 2024
1W 2.18 % 1M 1.84 % 3M -13.17 % 1Y 14.08 %

Key Metrics

Shape
  • Market Cap

    12.12B


  • Shares Outstanding

    95.37M


  • Share in Float

    89.52M


  • Dividende

    0


  • Earning Date

    06 Nov 2024


  • Price Target

    127.08


  • Average Volume

    960143


  • Beta

    0.808


  • Range

    55.25-173.25


  • Industry

    Biotechnology


  • Website

    https://www.sarepta.com


  • Sector

    Healthcare


Fundamentals

Shape

156.89x

P/E Ratio

8.05x

P/S Ratio

11.16x

P/B Ratio

1.1

Debt/Equity

3.1%

Net Margin

$0.8

EPS

How SRPT compares to sector?

P/E Ratio

Relative Strength

Shape

SRPT

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$3B

Shape760%

2025-Revenue

$11.13

Shape16200%

2025-EPS

$2B

Shape-17174%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Evercore ISI

upgrade

Previous: Not converted

2024-08-08

Now: Outperform

RBC Capital

upgrade

Previous: Sector Perform

2024-07-29

Now: Outperform

Citigroup

downgrade

Previous: Buy

2024-06-26

Now: Neutral

Piper Sandler

initialise

Previous: Not converted

2024-05-31

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-2.94
vs -0.60

Q4.22

arrow
arrow

N/A

-1.24
vs -1.42

Q1.23

arrow
arrow

N/A

-0.97
vs -1.20

Q2.23

arrow
arrow

N/A

-0.27
vs -2.65

Q3.23

arrow
arrow

N/A

-0.46
vs -2.94

Q4.23

arrow
arrow

+138%

0.47
vs -1.24

Q1.24

arrow
arrow

+175%

0.73
vs -0.97

Q2.24

arrow
arrow

+126%

0.07
vs -0.27

Q3.24

arrow
arrow

N/A

-0.07
vs -0.46

Q4.24

arrow
arrow

+190%

1.36
vs 0.47

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+22%

230.3M  vs 189.4M

Q4.22

arrow
arrow

+28%

258.4M  vs 201.5M

Q1.23

arrow
arrow

+20%

253.5M  vs 210.8M

Q2.23

arrow
arrow

+12%

261.2M  vs 233.5M

Q3.23

arrow
arrow

+44%

331.8M  vs 230.3M

Q4.23

arrow
arrow

+54%

396.8M  vs 258.4M

Q1.24

arrow
arrow

+63%

413.5M  vs 253.5M

Q2.24

arrow
arrow

+39%

362.9M  vs 261.2M

Q3.24

arrow
arrow

+23%

407.8M  vs 331.8M

Q4.24

arrow
arrow

+43%

567.6M  vs 396.8M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-60%

-0.60
vs -0.32

Q4.22

arrow
arrow

-28%

-0.28
vs -0.60

Q1.23

arrow
arrow

-73%

-0.73
vs -0.28

Q2.23

arrow
arrow

-3%

-0.03
vs -0.73

Q3.23

arrow
arrow

-5%

-0.05
vs -0.03

Q4.23

arrow
arrow

+5%

0.05
vs -0.05

Q1.24

arrow
arrow

+4%

0.04
vs 0.05

Q2.24

arrow
arrow

+1%

0.01
vs 0.04

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

403

403
vs 350

15%

Q4.22

arrow
arrow

446

446
vs 403

11%

Q1.23

arrow
arrow

464

464
vs 446

4%

Q2.23

arrow
arrow

442

442
vs 464

-5%

Q3.23

arrow
arrow

447

447
vs 442

1%

Q4.23

arrow
arrow

439

439
vs 447

-2%

Q1.24

arrow
arrow

446

446
vs 439

2%

Q2.24

arrow
arrow

528

528
vs 446

18%

Earnings Growth

Latest News